-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Regulatory Considerations Surrounding Novel Endpoints and Biomarker-Driven Clinical Trials in Myeloma

Program: Scientific Workshops @ ASH
Session: Integrating MRD into Clinical Trial Design and Clinical Practice
Thursday, December 3, 2020, 7:02 AM-7:42 AM

Nicole J. Gormley, MD

U.S. Food and Drug Administration, Bethesda, MD

Disclosures: No relevant conflicts of interest to declare.